This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Topic: medicines

October 12, 2009
The intake of patients for a phase III clinical trial of a lung-cancer drug has been suspended after the group being treated suffered more deaths than those who used established medicines

The intake of patients for a phase III clinical trial of a lung-cancer drug has been suspended after the group being treated suffered more deaths than those who used established medicines.

US pharmaceutical giant Pfizer decided not to expand the trial of its figitumumab product after its test group suffered more adverse events, including fatalities, The Wall Street Journal reported.